Clinical Trial Update: Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy [Phase 2]

View source ↗

Summary

A phase 2 clinical trial evaluated the combination of irinotecan and cetuximab as second-line therapy for colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Cancer
• Rectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Irinotecan (Irinotecan)

Snippet

Sponsor: University of Pittsburgh | Conditions: Colon Cancer, Rectum Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-07-12